Business Context and Reporting Period
This Form 8-K Current Report was filed by Pulse Biosciences, Inc. on November 3, 2017, regarding events occurring on November 2, 2017. The filing details a complete restructuring of the Company's Board of Directors, including the resignation of four directors and the election of four new directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation and legal fees:
- Legal Fees: Fees paid to Wilson Sonsini Goodrich & Rosati (WSGR) were approximately $31,000 for the fiscal year ended December 31, 2016, and approximately $466,000 for the period through October 31, 2017.
- Director Compensation: New non-employee directors receive an annual retainer of $25,000, plus additional retainers for committee service ($4,000 per committee) and chairmanship roles ($6,000 to $18,000 depending on the committee).
- Equity Grants: Each new director received a stock option to purchase 65,000 shares, vesting over three years.
Material Changes
The filing reports the following material changes to corporate governance:
- Resignations: Robert J. Greenberg, M.D., Ph.D., Robert M. Levande (Chairman), Mitchell E. Levinson, and Thierry B. Thaure resigned from the Board and all committee assignments effective immediately. The resignations were not due to any disagreement with the Company.
- Departure Compensation: Resigning directors received a lump-sum cash stipend equivalent to their prorated annual retainer, and all their equity awards were fully vested.
- New Appointments: Kenneth A. Clark, Robert W. Duggan, Thomas J. Fogarty, M.D., and Manmeet S. Soni were elected to the Board effective immediately.
- Leadership Changes: Robert W. Duggan was appointed Chairman of the Board. New committee chairs were appointed: Manmeet S. Soni (Audit Committee), Maky Zanganeh (Compensation Committee), and Kenneth A. Clark (Nominating and Corporate Governance Committee).
Outlook, Risks, and Unusual Items
Management Commentary and Background:
- Robert W. Duggan: A significant shareholder owning approximately 36% of the Company's common stock. He has extensive experience as a former Chairman and CEO of Pharmacyclics, Inc. and Computer Motion, Inc.
- Manmeet S. Soni: Brings recent experience as CFO of Alnylam Pharmaceuticals and ARIAD Pharmaceuticals.
- Thomas J. Fogarty, M.D.: A managing director of Emergent Medical Partners with a background in cardiovascular surgery.
- Kenneth A. Clark: A partner at WSGR with over 25 years of experience in biopharmaceutical strategic transactions.
Risks and Contingencies: The filing notes that the Company has granted registration rights to Mr. Duggan under previous Securities Purchase Agreements, with a registration statement for resale expected to be filed no earlier than January 2, 2018. No other risks or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the beneficial ownership percentage of Robert W. Duggan (stated as approx. 36%) and any potential conflicts of interest.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for the board overhaul.
- Confirm the vesting schedule and exercise price of the 65,000 share options granted to new directors.
- Monitor the upcoming filing of the registration statement for Mr. Duggan's shares, scheduled for no earlier than January 2, 2018.
- Check subsequent filings for the Company's financial status, as this 8-K contains no operational or financial performance data.